ERBB2 and cancer: Future work using consistent methods for assessing ER−/ER+ status, stratification of ER− cancers into HER2+ and triple negatives, analyzing multiple biopsies and conducting analyses using the proportion of cells staining positive for ER could help resolve these open questions.